REGENXBIO Inc.: management transactions · United States · SEC (Form 4)

About REGENXBIO Inc.

REGENXBIO Inc. is a U.S.-based biotechnology company listed on the Nasdaq market in the United States, focused on in vivo gene therapy. Headquartered in Rockville, Maryland, the company develops treatments intended to address severe genetic and degenerative diseases, with a particular emphasis on rare diseases and retinal disorders. Its core competitive asset is its proprietary NAV Technology platform, designed to support AAV-based gene delivery and durable therapeutic expression. Founded in 2009, REGENXBIO has evolved into a recognized gene-therapy developer through a mix of internal R&D and strategic pharmaceutical partnerships. ([ir.regenxbio.com](https://ir.regenxbio.com/?utm_source=openai)) The company’s pipeline is centered on several clinical and pre-commercial programs. The most advanced asset is RGX-202, a gene therapy candidate for Duchenne muscular dystrophy. In 2025 and 2026, REGENXBIO reported encouraging interim data, completed pivotal enrollment, and began commercial production activities, with top-line pivotal data expected in early Q2 2026 and a BLA filing targeted for mid-2026. In rare lysosomal diseases, the company is developing RGX-121 for MPS II and RGX-111 for MPS I through a partnership with Nippon Shinyaku. In ophthalmology, REGENXBIO is advancing ABBV-RGX-314 with AbbVie for wet AMD and diabetic retinopathy. ([ir.regenxbio.com](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-completion-pivotal-enrollment-and-initiates/?utm_source=openai)) From a commercial perspective, REGENXBIO is still largely a development-stage company, but its risk-reward profile has improved as its lead programs move closer to potential approval. Its competitive positioning is built on a combination of proprietary platform know-how, integrated manufacturing capabilities, and a pipeline aimed at high-unmet-need indications. The company manufactures RGX-202 at its Manufacturing Innovation Center in Rockville, which strengthens supply-chain control and could support future launch readiness. ([ir.regenxbio.com](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-completion-pivotal-enrollment-and-initiates/?utm_source=openai)) Geographically, REGENXBIO remains primarily U.S.-anchored, with headquarters, research, and manufacturing operations in the United States, while its partnerships broaden potential commercialization into international markets. Agreements with AbbVie and Nippon Shinyaku extend the company’s reach and validate its technology platform. Recent highlights include continued positive data for RGX-202, ongoing regulatory progress for RGX-121, and manufacturing scale-up tied to a possible mid-2026 launch path. For European investors, this is a high-upside biotech name, but one that remains highly dependent on clinical execution, regulatory decisions, and eventual market adoption. ([ir.regenxbio.com](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-reports-new-positive-interim-data-phase-iii-affinity/?utm_source=openai))